The Pharma Data

JULY 27, 2021

Amgen’s R&D resources and its extensive clinical experience in immuno-oncology are ideally suited to applying and advancing Teneobio’s differentiated technologies and multispecific antibodies to deliver transformative medicines,” said Roland Buelow, Ph.D., chief executive officer of Teneobio.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

NOVEMBER 8, 2023

Annemie Deiteren, MD, PhD, Director, Translational Medicine & Clinical Pharmacology, Translational Medicine & Early Development, Sanofi, on: ‘Multispecific, multivalent TSLP-IL13 NANOBODY’. Chairperson Mark Chiu, on: ‘Strategies to enhance efficacy of a tetraspecific antibody to TNBC and PDAC’.

Antibody 62

Antibody Engineer Protein Scientist 62

Drug Discovery World

NOVEMBER 9, 2023

Benjamin Hackel, PhD, Professor, Chemical Engineering & Materials Science, University of Minnesota, on: ‘Engineering hyperstable synthetic miniproteins as developable ligands’. James Cooke, PhD, Associate Director, Bicycle Therapeutics, on: ‘Engineering bicyclic peptides for precision targeted medicine’.

Engineer 52

Engineer Antibody Protein In-Vivo 52